SPRO Spero Therapeutics

Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025

Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025

CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its third quarter 2025 financial results and provide a business update on Thursday, November 13, after the market close. The Company does not intend to host a conference call.

About Spero Therapeutics

Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with high unmet need. For more information, visit

Spero Investor Relations Contact:

Shai Biran, PhD

Spero Therapeutics

Spero Media Inquiries: 



EN
04/11/2025

Underlying

SPROSpero Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Spero Therapeutics

 PRESS RELEASE
Free
SPRO Spero Therapeut...

Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operati...

Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025In February, Spero’s licensing partner, GSK announced the FDA had set the PDUFA date as June 18, 2026 Spero estimates cash and cash equivalents as of December 31, 2025 are sufficient to fund current operations into 2028 CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SPRO), a clinic...

March 26, 2026 1 EN
 PRESS RELEASE
Free
SPRO Spero Therapeut...

Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financi...

Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026 CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a business update on Thursday, March 26, 2026, after market close. The Company does not intend to host a conf...

March 18, 2026 1 EN
 PRESS RELEASE
Free
SPRO Spero Therapeut...

Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA fo...

Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that its development partner, GSK, filed a New Drug Application (NDA) resubmission to the U.S. Food and Drug Administration (FDA) for tebipenem HBr, an investigational oral carbapenem...

December 19, 2025 1 EN
 PRESS RELEASE
Free
SPRO Spero Therapeut...

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rul...

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Nov. 28, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on November 3, 2025, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 90,000 restricted stock unit awards (RSUs) to one new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive ...

November 28, 2025 1 EN
 PRESS RELEASE
Free
SPRO Spero Therapeut...

Spero Therapeutics Announces Third Quarter 2025 Operating Results and ...

Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update Results from PIVOT-PO Phase 3 trial evaluating tebipenem HBr in complicated urinary tract infection (cUTI) presented as IDWeek late-breaker in October 2025Spero’s development partner, GSK, plans to submit data from the PIVOT-PO trial as part of a planned US Food and Drug Administration (FDA) filing in 4Q 2025 Company expects current cash and cash equivalents to fund operations into 2028 CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutic...

November 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch